Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC Plus Erlotinib in Nasopharyngeal Cancer
NCT00603915Phase 2Completed
- Sponsor
- University Health Network
- Start
- Jun 2006
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in nasopharyngeal carcinoma (NPC), sponsored by University Health Network. Primary endpoint: Progression Free Survival. Started Jun 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00603915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603915.